Patient characteristics
| Characteristic . | N = 120 . |
|---|---|
| Male, n (%) | 58 (48.3) |
| Age, median (range), y | 63 (42-87) |
| Creatinine, median (range) | 0.9 (0.44-2.5) |
| LDH, median (range) | 170.5 (79-1353) |
| Hemoglobin, median (range) | 10.4 (6.4-14.6) |
| Albumin, median (range) | 3.5 (0.7-4.5) |
| B2M, n = 105, median (range) | 3.5 (1.2-40.4) |
| % Ki67/CD138, n = 88, median (range) | 7.5 (0-85) |
| Calcium, median (range) | 9.1 (7.8-12.3) |
| % BM plasmacytosis, n = 111, median (range) | 62.5 (0-100) |
| Prior MGUS, n (%) | 9 (7.5) |
| Prior smoldering myeloma, n (%) | 18 (15) |
| Cytogenetics, n = 113, n (%)* | |
| High risk (R-ISS defining) | 39 (35) |
| Del 17p or loss of P53 | 28 (25) |
| t(4;14) | 11 (10) |
| t(14;16) | 6 (5) |
| Additional high-risk markers | |
| t(14;20) | 1 (1) |
| Gain (1q) | 47 (42) |
| Loss (1p) | 16 (14) |
| Karyotype del 13q | 13 (2) |
| Stage | |
| R-ISS, n = 100, % | |
| 1 | 18 |
| 2 | 64 |
| 3 | 18 |
| ISS, n = 105, n (%) | |
| 1 | 42 (40) |
| 2 | 37 (35) |
| 3 | 26 (25) |
| M-protein isotype, n (%) | |
| IgG-κ | 44 (37) |
| IgG-λ | 27 (23) |
| IgA-κ | 14 (12) |
| IgA-λ | 13 (11) |
| Free κ | 14 (12) |
| Free λ | 5 (4) |
| IgD-κ | 2 (2) |
| IgM-κ | 1 (1) |
| Characteristic . | N = 120 . |
|---|---|
| Male, n (%) | 58 (48.3) |
| Age, median (range), y | 63 (42-87) |
| Creatinine, median (range) | 0.9 (0.44-2.5) |
| LDH, median (range) | 170.5 (79-1353) |
| Hemoglobin, median (range) | 10.4 (6.4-14.6) |
| Albumin, median (range) | 3.5 (0.7-4.5) |
| B2M, n = 105, median (range) | 3.5 (1.2-40.4) |
| % Ki67/CD138, n = 88, median (range) | 7.5 (0-85) |
| Calcium, median (range) | 9.1 (7.8-12.3) |
| % BM plasmacytosis, n = 111, median (range) | 62.5 (0-100) |
| Prior MGUS, n (%) | 9 (7.5) |
| Prior smoldering myeloma, n (%) | 18 (15) |
| Cytogenetics, n = 113, n (%)* | |
| High risk (R-ISS defining) | 39 (35) |
| Del 17p or loss of P53 | 28 (25) |
| t(4;14) | 11 (10) |
| t(14;16) | 6 (5) |
| Additional high-risk markers | |
| t(14;20) | 1 (1) |
| Gain (1q) | 47 (42) |
| Loss (1p) | 16 (14) |
| Karyotype del 13q | 13 (2) |
| Stage | |
| R-ISS, n = 100, % | |
| 1 | 18 |
| 2 | 64 |
| 3 | 18 |
| ISS, n = 105, n (%) | |
| 1 | 42 (40) |
| 2 | 37 (35) |
| 3 | 26 (25) |
| M-protein isotype, n (%) | |
| IgG-κ | 44 (37) |
| IgG-λ | 27 (23) |
| IgA-κ | 14 (12) |
| IgA-λ | 13 (11) |
| Free κ | 14 (12) |
| Free λ | 5 (4) |
| IgD-κ | 2 (2) |
| IgM-κ | 1 (1) |
B2M, β2-microglobulin; BM, bone marrow; ISS, International Staging System; LDH, lactate dehydrogenase; MGUS, monoclonal gammopathy of undetermined significance.
Patients with multiple high-risk abnormalities were included with each abnormality.